Vitekta (elvitegravir) / Japan Tobacco, Gilead - LARVOL DELTA

Partial post-exposure protection by topical inserts containing tenofovir alafenamide fumarate/elvitegravir in a macaque model of rectal SHIV infection. (PubMed, J Infect Dis) - "Here, we show that the same inserts provide significant post-exposure protection (82.9% efficacy) when applied four hours after SHIV exposure. Our findings further support the ongoing clinical development of TAF/EVG inserts for on-demand HIV prevention."

Journal • Human Immunodeficiency Virus • Infectious Disease

Deep sequencing reveals underestimated burden of integrase inhibitor resistance mutations in people living with HIV: a global individual patient data meta-analysis. (PubMed, Emerg Microbes Infect) - "IPD analysis of 394 mutation-positive individuals revealed 8.52% low-frequency resistance to dolutegravir and bictegravir in treatment-naïve populations, while treated patients exhibited significantly increased intermediate/high-level resistance to first-generation INSTIs, including raltegravir and elvitegravir. Although second-generation INSTIs maintain lower resistance rates, cross-resistance risks necessitate clinical vigilance. Optimized resistance surveillance strategies incorporating low-frequency mutation detection offer critical evidence for advancing global HIV control efforts."

Journal • Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Curcumin-enhanced elvitegravir therapy mitigates neuroinflammation and cognitive deficits in EcoHIV mice. (PubMed, Exp Biol Med (Maywood)) - "These findings demonstrate that the EVG + CUR combination effectively targets both viral persistence and the underlying neuroinflammatory and oxidative mechanisms driving HAND. By improving cognitive and motor function while mitigating neuroinflammation and oxidative stress, EVG + CUR represents a promising adjunctive therapy for HAND, offering a multifaceted approach to addressing the complex pathophysiology of HIV-associated neurocognitive disorders."

Journal • Preclinical • CNS Disorders • Cognitive Disorders • Developmental Disorders • Human Immunodeficiency Virus • Infectious Disease • Inflammation • IL1B • IL6 • TNFA

Prevalence of primary HIV-1 drug resistance among antiretroviral-naïve individuals in Togo in 2023: a national study. (PubMed, Front Public Health) - "However, accessory mutations (genetic changes that do not confer significant resistance by themselves) as E157Q/E157EQ (43/57) and T97A/T97TA (14/57) associated with resistance against first-generation integrase inhibitors (INIs) as raltegravir, elvitegravir were found in 17.2% of samples. The dominant subtypes were CRF02_AG (64.8%) and CRF06_cpx (12.8%). These results support the continued use of dolutegravir-based regimens in Togo and call for continued monitoring of primary resistance to maintain the effectiveness of therapeutic strategies in Togo."

Journal • Human Immunodeficiency Virus • Infectious Disease

A Rare Case of Diffuse Esophageal Intramural Pseudodiverticulosis! (ACG 2025) - "Medications included a combination of elvitegravir, cobicistat, emtracitibine, and tenofovir alafenamide in addition to colchicine and atorvastatin. Management aims at controlling the underlying inflammation, relieving the patients' symptoms and treating the coexisting esophageal conditions. Despite that EIPD is considered a benign clinical entity, serious complications can occur including esophageal stricture, esophageal dysmotility, esophageal perforation, intra-mediastinal fistula, mediastinitis, and lung abscess.Figure: Esophageal Intramural Pseudo-DiverticulosisFigure: Pathology"

Clinical • Candidiasis • CNS Disorders • Depression • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Gout • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Inflammatory Arthritis • Psychiatry • Rheumatology • CD4

Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes. (PubMed, Clin Infect Dis) - "Individual INSTI-based regimens among treatment-experienced AYAPHIV had moderate effectiveness with respect to viral suppression. Continued average weight gain across INSTIs raises concerns about long-term cardiometabolic sequalae."

Journal • Human Immunodeficiency Virus • Infectious Disease • Obesity • Pediatrics • CD4

Differences in ART regimen initiation among people with recently acquired HIV: 2015-2021 (EACS 2025) - "INSTIs were classified as first-generation (raltegravir, elvitegravir) or second-generation (dolutegravir, bictegravir). However, women and individuals from Africa remain less likely to receive these regimens despite early care engagement. Qualitative research with prescribers is needed to understand these disparities to inform more equitable ART initiation."

Human Immunodeficiency Virus • Infectious Disease • CD4

Nucleocapsid mutations at time of virological failure with an integrase inhibitor (EACS 2025) - "Results : Sequences were available for 61 PLWH-1 receiving either elvitegravir (n=3), raltegravir (n=4), cabotegravir (n=4), dolutegravir (n=18), or bictegravir (n=32). Conclusions : Our study confirms that mutations in the nucleocapsid are observed in a small number of individuals with VF with an INSTI-based regimen. Phenotypic data are needed to decipher the impact of the new mutations (F16Y, N27D, and N27H), and the frequency of nucleocapsid mutations should be explored in larger cohorts."

Human Immunodeficiency Virus • Infectious Disease

Integrated Population Pharmacokinetic-pharmacodynamic Modeling of HIV Virus-host Infection Dynamics in Patients Undergoing Antiretroviral Monotherapy. (PubMed, AAPS J) - "This work aims to develop a single and fully identifiable population semi-mechanistic pharmacokinetic/pharmacodynamic (popPKPD) model integrating data (drug levels, CD4 + T cells and viral RNA) of five different antiretroviral (ARV) drugs administered in monotherapy: lenacapavir, bictegravir, tenofovir alafenamide, emtricitabine and elvitegravir. The popPKPD model was able to capture key aspects of viral dynamics, drug behaviour, and treatment response. The models developed will serve as a useful tool for further development and optimization of these HIV therapies, especially when evaluating multiple ARVs to be administered in a novel combination setting."

Journal • Monotherapy • PK/PD data • Human Immunodeficiency Virus • Infectious Disease • CD4

Talaromyces Marneffei Infection Involving the Central Nervous System in a Patient with Acquired Immunodeficiency Syndrome: A Case Report and Literature Review. (PubMed, Int J Infect Dis) - "CNS Talaromyces marneffei infection in AIDS patients often lacks specific clinical manifestations, which complicates diagnosis and treatment. This case report contributes to the existing body of knowledge by presenting a successfully managed case, thereby enhancing the understanding of diagnostic and therapeutic strategies for similar future presentations."

Journal • Review • CNS Disorders • Dermatology • Epilepsy • Human Immunodeficiency Virus • Infectious Disease

Immediate and delayed switches to tenofovir DF-containing, ainuovirine-based antiretroviral regimen: the SPRINT extensional study. (PubMed, BMC Med) - P3 | "Both ISG and DSG maintained high viral Suppression in PLWH through 96 weeks. DSG could offset weight gain and dyslipidemia associated with previous exposure to E/C/F/TAF."

Clinical • Journal • Dyslipidemia • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • Psychiatry

Prevalence of acquired resistance to HIV integrase strand transfer inhibitors (INSTIs) in clinical samples from treatment-experienced patients in Chile, 2012-2023. (PubMed, J Virus Erad) - "High AR rates were observed for first-generation INSTIs: raltegravir (28 %) and elvitegravir (27.7 %). Lower resistance levels were found for dolutegravir (8.3 %), bictegravir (8.3 %), and cabotegravir (18.7 %)...These findings highlight the need for nationwide molecular surveillance and pre-treatment genotyping, particularly before initiating long-acting regimens such as CAB-LA. Strategic monitoring will be critical to maintaining the efficacy of current and next-generation INSTIs."

Journal • Preclinical • Human Immunodeficiency Virus • Infectious Disease

Confronting Dual Therapeutic Hurdles in Advanced HIV: A Case Report on INSTIs Resistance and Talaromyces marneffei Coinfection. (PubMed, Int Med Case Rep J) - "Antiretroviral therapy (ART) was switched from elvitegravir to zidovudine, lamivudine, dolutegravir, and albuvirtide. Antifungal therapy adjusted from voriconazole to itraconazole...This case emphasizes genotype resistance testing-guided ART modification and rigorous opportunistic infection management in drug-resistant HIV patients. Coordinated care and timely interventions can enhance the outcomes in high-risk cases."

Journal • Human Immunodeficiency Virus • Infectious Disease • CD4

Switch to bictegravir/emtricitabine/tenofovir alafenamide in people living with HIV aged 65 years or older: BICOLDER study - IMEA 057. (PubMed, J Infect Public Health) - "The findings indicate that B/F/TAF is both safe and effective for elderly PWH patients with a prolonged and documented history of HIV infection, multiple co-morbidities and concomitant medication."

Journal • Cardiovascular • CNS Disorders • Human Immunodeficiency Virus • Infectious Disease • Mood Disorders • Psychiatry

Untargeted Metabolite Profile Associations with Body Mass Index, Waist-Hip Ratio, and Antiretroviral Therapy in >1300 People with HIV: the Swiss HIV Cohort Study. (PubMed, J Infect Dis) - "In PWH from Switzerland, untargeted metabolite profiling revealed multiple unreported associations with different ART agents, and previously reported associations with BMI."

Journal • Genetic Disorders • Human Immunodeficiency Virus • Infectious Disease • Obesity

Exploring the Potential of HIV Integrase Inhibitors as Therapeutic Agents Against HSV and HCMV: A Molecular Docking Study. (PubMed, J Exp Pharmacol) - "Among the anti-HIV drugs tested, Elvitegravir and raltegravir were most effective in controlling the HSV-1 and HSV-2 infections at concentrations as low as 1.6 µg/mL when tested with 10TCID50 viral challenge dose. The tested FDA approved drug molecules showed the potential to be repurposed as an antiHSV and antiHCMV agent. The in silico and in vitro results warrant further investigation in preclinical and clinical studies to validate its therapeutic potential and safety for HSV-related infections."

Journal • Herpes Simplex • Human Immunodeficiency Virus • Infectious Disease

High-performance hairpin-whiptail DNA target for HIV-1 integrase assay. (PubMed, Int J Biol Macromol) - "The hairpin-whiptail target DNA yielded an excellent Z' score of 0.758 with the qPCR-based integrase activity assay making it suitable for screening compound libraries and determination of IC50 as demonstrated with elvitegravir. While the hairpin-whiptail target DNA was specifically designed for the qPCR integrase activity assay, it could easily be adapted to improve the performance of other integrase assays."

Journal • Human Immunodeficiency Virus • Infectious Disease

Comparative effectiveness of modern antiretroviral therapy regimens among people living with HIV in China: a multicenter cohort study (IAS-HIV 2025) - "Most frequently used third ART drugs included nevirapine, efavirenz, dolutegravir, lopinavir, and others (including darunavir, raltegravie, elvitegravir and rilpivirine). Our findings further reinforce the positioning of dolutegravir-based regimens as preferred options in LMICs."

Clinical • HEOR • Human Immunodeficiency Virus • Infectious Disease • CD4

HIV-1 Genetic Diversity and Transmitted Drug Resistance Mutations in ART-Naïve Individuals in South Korea from 2021 to 2024. (PubMed, Viruses) - "The integrase strand transfer inhibitor drugs, elvitegravir and raltegravir, most frequently exhibited high resistance scores. We provide a comprehensive overview of the HIV-1 genetic distribution and TDR patterns in South Korea from 2021 to 2024. Within the broader context of HIV-1 epidemiology in Asia and the Pacific, the findings contribute to a comprehensive understanding of the global distribution of HIV-1 resistance and genotypes, enabling the development of effective interventions."

Journal • Human Immunodeficiency Virus • Infectious Disease

METTL3-Driven m6A Modifications in Esophageal Squamous Cell Carcinoma: Emerging Mechanisms, Biomarker Potential, and Therapeutic Innovations. (PubMed, Eur J Pharmacol) - "Emerging therapeutic strategies targeting METTL3, including small-molecule inhibitors [e.g., Elvitegravir] and RNA-based interventions, demonstrate preclinical efficacy in suppressing ESCC proliferation and metastasis. This review also identifies critical knowledge gaps, such as the interplay between METTL3 and tumor microenvironment dynamics, and advocates for multicenter studies to validate its clinical applicability. Collectively, our findings position METTL3 as a promising biomarker and a tractable therapeutic target, offering actionable insights to advance ESCC management."

Biomarker • Journal • Review • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma • EGR1 • METTL3 • SLC2A1

Impact of switching to bictegravir- or dolutegravir-based antiretroviral therapy on weight in people living with HIV during the COVID-19 pandemic. (PubMed, Curr Med Res Opin) - "Patients aged 18 years and older were included if they switched from raltegravir- or elvitegravir-based to DTG- or BIC-based regimens (Group 1), from non-INSTI-based to DTG- or BIC-based regimens (Group 2), or remained on non-INSTI-based regimens (Group 3). Switching to BIC- or DTG-based regimens during the COVID-19 pandemic was not associated with weight gain in treatment-experienced, virologically-suppressed PLWH in this single-center study. The study findings may reassure clinicians who are hesitant about switching treatment-experienced patients to newer BIC- or DTG-containing regimens due to concerns about potential weight gain."

Journal • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease

Neuropsychiatric adverse events in people with HIV initiating a new integrase strand transfer inhibitor-based regimen in Italy: findings from the NEURO-INSTI study. (PubMed, BMC Infect Dis) - "Among PWH on INSTI treatment, IVDUh, concurrent psychiatric illness, abacavir and RAL use increased the risk of CNS/NP AEs occurrence. PWH on BIC were less likely to experience CNS/NP AEs and related treatment discontinuations."

Adverse events • Journal • CNS Disorders • Human Immunodeficiency Virus • Infectious Disease • Mental Retardation • Psychiatry • CD4

Salvage therapy with an Albuvirtide-based antiretroviral regimen for multi-drug resistant HIV and drug-resistant HBV with renal impairment: a case report. (PubMed, Virol J) - "This case underscores the potential value of individualized treatment strategies for patients with multidrug-resistant HIV and HBV co-infection complicated by renal impairment. The observed virological control following the use of novel agents such as Albuvirtide (ABT), in combination with second-generation integrase strand transfer inhibitors (INSTIs) like DTG, alongside renal-sparing antivirals, highlights the importance of designing optimized regimens based on resistance profiles and renal function. This personalized and adaptive therapeutic approach may offer clinical benefits in similarly complex scenarios."

Journal • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Nephrology • Renal Disease

Investigation of Integrase Inhibitor Resistance Mutations in gp41 in Clinical Samples. (PubMed, J Acquir Immune Defic Syndr) - "While off-target INSTI substitutions may arise in vivo, there is currently insufficient evidence to recommend expanding INSTI resistance testing to include Env."

Journal • Human Immunodeficiency Virus • Infectious Disease

PLGA-Encapsulated Elvitegravir and Curcumin Modulates ART Penetration, Oxidative Stress, and Inflammation. (PubMed, Brain Sci) - "These findings highlight the potential of nanoparticle-based ART strategies to address limitations in current regimens and pave the way for more effective HAND therapies. Future studies should focus on optimizing formulations and evaluating safety in chronic HIV settings."

Journal • CNS Disorders • Cognitive Disorders • Developmental Disorders • Human Immunodeficiency Virus • Infectious Disease • Inflammation • GFAP • IL18 • IL1B • L1CAM • SYP • TNFA